Conditions: Non-small Cell Lung Cancer
Keywords: Lung cancer advanced second or third line
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 188
Healthy volunteers: no

Brief summary:
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one of these drugs, and followed for efficacy and tolerance of each.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Erlotinib intervention 2: PF-00299804
Intervention descriptions: intervention 1: Continuous oral dosing at 150 mg daily. intervention 2: Continuous oral dosing at 45mg daily

Protocol document: